CD8 T-cell responses in incident and prevalent human papillomavirus types 16 and 18 infections.
CD8 T-cell responses in incident and prevalent human papillomavirus types 16 and 18 infections.
复制标题
DOI：
10.5402/2012/854237
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Nakagawa M
中科院分区：
文献类型：
--
作者：
Coleman HN;Moscicki AB;Farhat SN;Gupta SK;Wang X;Nakagawa M
在发生（阴性访视后新发）或流行（持续≥ 4个月）人乳头瘤病毒16型（HPV 16）或人乳头瘤病毒（HPV 18）感染的受试者中检查CD 8 T细胞应答。这些组是从每4个月进行宫颈细胞学和HPV-DNA检测的女性队列中选择的。酶联免疫斑点（ELISPOT）试验在入组时（零时）和一年后进行。在零时，17例发生HPV 16/18感染的受试者中有1例（6%）ELISPOT结果阳性，1年时增加至6例（35%）。对于HPV 16/18感染的受试者，ELISPOT结果在零时（15例受试者中有2例（15%）阳性）和1年时（3例（20%））相似。虽然所有11名HPV 16感染的女性在一年后都显示出清除，但出乎意料的是，4名HPV 18感染的女性中只有1名（25%）在一年后显示出清除（P = 0.009）。
CD8 T-cell responses were examined in subjects with incident (new following negative visits) or prevalent (lasting ≥ 4 months) human papillomavirus type 16 (HPV16) or human papillomavirus (HPV18) infection. The groups were chosen from a cohort of women being followed every 4 months with cervical cytology and HPV-DNA testing. Enzyme-linked immunospot (ELISPOT) assay was performed at enrollment (time zero) and one year later. At time zero, 1 (6%) of 17 subjects with incident HPV 16/18 infections had positive ELISPOT results which increased to 6 (35%) at one year. For the subjects with prevalent HPV 16/18 infections, the ELISPOT results were similar at time zero (2 (15%) of 15 subjects positive) and at one year (3 (20%)). While all of the 11 women with prevalent HPV16 infection showed clearance one year later, unexpectedly only 1 (25%) of 4 women with prevalent HPV18 infection demonstrated clearance one year later (P = .009).